Naturex, Inc. engages in the manufacture, marketing and distribution of natural ingredients for the food, pharmaceutical and cosmetic industries. The company is headquartered in South Hackensack, NJ.

Sandoz AG, a subsidiary of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

CPEX Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company, incorporated in the state of Delaware, with principal executive offices located at 2 Holland Way, Exeter, New Hampshire. We are in the business of research and development of pharmaceutical products utilizing our validated drug delivery platform technology. We have U.S. and international patents and other proprietary rights to technology that facilitates the absorption of drugs. Our platform drug delivery technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through development of proprietary formulations with molecules such as CPE-215Â:registered:. Our first product is TestimÂ:registered:, a gel for testosterone replacement therapy, which is a formulation of our technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc. (“Auxilium”), which is currently marketing it in the United States, Europe and other countries. We have an additional licensed application with Serenity Pharmaceuticals, Inc. ("Serenity") for Ser-120, a product candidate for the treatment of nocturia. Ser-120, which is currently in multiple Phase 3 trials, utilizes our patented intranasal drug delivery technology. In 2010, Allergan, Inc. assumed our exclusive license agreement with Serenity.

Koyo Sangyo Co. Ltd. is a private company headquartered in Tokyo, Japan, with operations in JP and CN, that manufactures and distributes wood and plastics products.

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing, and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centers in Denmark and China.

AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE.

CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.

Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

Medingo Ltd. engages in developing a tiny insulin pump that allows people with diabetes to deliver insulin discreetly without tubing or injections. Medingo's product is Solo MicroPump. The company was founded on November 2, 2005 and is headquartered in Tel Aviv, Israel.

SSP Co., Ltd. engages in the manufacture and sale of pharmaceuticals, quasi-drugs and cosmetics. The company was founded in 1765 and is headquartered in Tokyo, Japan.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Medtronic MiniMed, Inc. manufactures insulin pumps and glucose monitoring systems. Its products include minimed 530g system, smartguard, enlite sensor, minimed revel and infusion sets. The company was founded by Alfred E. Mann in 1979 and is headquartered in Northridge, CA.

Harbin Boda Senhu Pharmaceutical Technology Co., Ltd., established on 2020-07-17, Business scope includes technology development,technical consulting,Technical Services,technology transfer,Technology Promotion;Conference Services;Import and export of goods or technology(Need to report to the relevant department);Sales:medical instruments,Chemical raw materials and products(Removal of hazardous chemicals,Chemicals,civilian explosives,precursor chemicals),Monitoring equipment,laboratory apparatus,disinfectant(Does not contain dangerous goods),hygiene products,daily necessities,cosmetic,Health Supplies,Office Supplies,filter element,Plastics and Plastic Products,Equipment,electronic product,Wujinjiaodian,Instrumentation and spare parts;food business;Accept entrustment to engage in house leasing;property management.

Part of Roche Holding AG, Roche Diabetes Care GmbH is a German company located in Mannheim that develops medicines and medical equipment. It was founded in 2014. Michael Wöhler is currently the CEO of the firm.\nThe company says this about itself: Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines. Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Amylin Pharmaceuticals is a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs. Develops a line of diagnostic and therapeutic products for diabetics. Working towards a cure for diabetes by challenging science, changing lives. Amylin employees are dedicated in their ability to "think outside the box". Because of our commitment of constantly finding newer and better ways to treat diabetes, we come to work each day feeling like we CAN make a difference in our world.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.